Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
desktop iconMarkt Monitor

Esperite (voorheen Cryo Save)« Terug naar discussie overzicht

Esperite 2016

3.912 Posts
Pagina: «« 1 ... 68 69 70 71 72 ... 196 »» | Laatste | Omlaag ↓
  1. forum rang 4 Nel 24 mei 2016 08:48
    quote:

    machmit schreef op 18 mei 2016 15:40:

    [...]
    16 mrt. 2015 - NEW YORK (GenomeWeb) – Illumina and its wholly-owned subsidiary Verinata Health have filed a patent infringement suit against Premaitha ... Illumina (Nasdaq: ILMN) announced that it and its wholly-owned subsidiary, Verinata Health Inc., (together “Illumina”) have filed a patent infringement suit against Premaitha Health plc in the High Court of Justice, Chancery Division, Patents Court in the United Kingdom.

    Illumina Patent Infringement Proceedings Update. Manchester, UK – 1 October 2015 - Premaitha Health plc ("Premaitha" AIM: NIPT) an innovative molecular ... Manchester, UK – 1 October 2015 - Premaitha Health plc ("Premaitha" AIM: NIPT) an innovative molecular diagnostics company employing the latest advances in DNA analysis technology to develop tests for non-invasive prenatal testing (NIPT) has been informed that Illumina, Inc. has today added a third patent to the two previously asserted in a UK patent suit against Premaitha in the High Court of Justice, Chancery Division, Patents Court in the UK.
    The patent asserted in this filing is EP2183693.
    The Directors believe that the IONA® test does not infringe these patents as claimed by Illumina and the alleged infringement is unfounded.
    -Ends-

    8 jan. 2016 - Premaitha continues to make a robust defence against earlier claims by Illumina and the Board is confident that the IONA® test does not ... Manchester, UK – 8 January 2016 – Premaitha Health PLC (AIM: NIPT, “Premaitha” or the “Company”), developer of the IONA® test, the first CE-marked non-invasive prenatal (NIPT) in vitro diagnostic kit, notes that Illumina, Inc. has today announced two patent infringement suits in Europe, one of which is against Premaitha’s customer in Poland. Illumina has also today taken similar action against Ariosa Diagnostics, a subsidiary of Roche, and their customer, The Doctors Laboratory, in the UK.
    Premaitha continues to make a robust defence against earlier claims by Illumina and the Board is confident that the IONA® test does not infringe the patents as claimed in the earlier cases or in relation to today’s announcement.
    Dr Stephen Little, CEO of Premaitha said: “These lawsuits are a continuation of attempts by Illumina to restrict competition in the European NIPT market. We believe pregnant women should not be denied choice in their decisions for prenatal care. Despite these distractions, we have made strong progress with our best-in-class IONA® test. We will support our customers against such actions and we look forward to announcing new contract wins in new international territories in the near future.”
    -Ends-

    26 jan. 2016 - No date has currently been set for the proceedings of the second claim lodged by Illumina in October 2015. The Company understands these ... Manchester, UK – 26 January 2016: Premaitha Health PLC (“Premaitha” or “the Company”; AIM: NIPT) provides investors with visibility of the timelines involved in the UK litigation previously lodged by Illumina.
    The Company has been advised that a date has now been set for the High Court to hear the first claim lodged by Illumina in March 2015. These proceedings will take place in early October 2016 and the outcome is likely to be known by Christmas 2016, subject to any appeals.
    No date has currently been set for the proceedings of the second claim lodged by Illumina in October 2015. The Company understands these will not be before 1 January 2017.
    Dr Stephen Little, CEO, Premaitha commented: “We fully understand that investors are keen for clarification on how the legal process in the UK will unfold. Therefore, as we have done today, we will continue to update investors as and when possible even though the process is inherently complex, timelines uncertain and much detailed information must by necessity remain confidential.
    “We continue to defend these actions robustly and we remain focused on delivering patient choice through high quality non-invasive prenatal testing in the UK and internationally."
    - Ends -

    In arriving at this decision, the Court accepted Premaitha's argument that the patents in question are all closely connected and that only a combined trial would allow all relevant matters to be addressed appropriately. The October 2016 trial date has therefore been cancelled.

    In addition, the Company's application to include an antitrust defence and counterclaim was presented to the Court. Premaitha alleges that Illumina's actions raise serious anticompetitive issues. The Court ordered that Illumina has until 28 May 2016 to present any arguments as to why Premaitha's application to include the antitrust defence and counterclaim should not be accepted.

    Stephen Little, CEO, said: "The Court accepted our position that these three patents are all centred on the same technology. As a result, the Court has adopted the timetable suggested by Premaitha, meaning all patent claims will be assessed simultaneously. We continue to believe the patents held by Illumina are invalid and that, in any event, the IONA® test does not infringe them.

    "We are also very pleased that the Company's antitrust defence has been presented to the Court and will be heard again within two months. We have long believed that Illumina's motivation in pursuing these claims is to protect and extend its dominant position in the next generation sequencing market. If such anticompetitive conduct is allowed to go unaddressed by the UK courts, it will have severe repercussions for the non-invasive prenatal screening market, reducing choice and slowing down innovation in the clinical management of pregnant women.

    "In our view, the decisions at the CMC provide a good platform for us to make our case to the Court and we remain confident that we will prevail. In addition, the removal of the October trial date allows us to continue to build on our current business momentum, accelerating growth and adoption of the IONA® test, unencumbered by an imminent court date. We remain focused on offering expectant parents the choice to use our safe, accurate and regulated non-invasive test wherever they are in the world."
    20 april 2016
  2. machmit 24 mei 2016 14:40
    quote:

    A3aantje schreef op 24 mei 2016 14:17:

    Blijft toch een ondoorgrondelijk fonds dat steeds na een opleving weer flink terug valt. Oppassen dus met je geld hier in te stoppen.
    Je moet altijd oppassen om je geld ergens in te stoppen. Kijk maar naar grote pensioenfondsen. Hier gaat het om een aandeel dat veelbelovend is en of die verwachting wordt bevestigd horen we binnenkort: 9 juni.
  3. forum rang 6 sportliefhebber 26 mei 2016 18:11
    quote:

    WMB strateeg schreef op 22 mei 2016 15:46:

    Beste forum leden,
    We weten allemaal dat Esperite op de wat langere termijn een sterke groei zal laten zien. Bij de huidige volumes kunnen we voorkomen dat Esperite onder de eur 2 komt. Wanneer een groot deel van de forum leden een klein aantal aandelen Esperite zou bijkopen wanneer de koers onder de eur 2 dreigt te komen (kan al vanaf 100 aandelen) dan ontstaat er een soort beleggingsclub van vele kleinere beleggers die samen een strategie afspreken. Dan wordt de koers stabieler. Ik heb dit in het verleden als eens gedaan met een ander fonds en het werkt! Voorwaarde is dan wel dat je als forum lid geen paniek verkopen doet! Anders heeft het geen zin. Ik heb de indruk dat de wat grotere beleggers paniek willen zaaien bij de kleinere beleggers. Maar onthoud: vele kleintjes zijn samen een grote. Dit werkt enkel met kleine fondsen met weinig uitstaande verhandelbare aandelen.Denk er maar eens over na. De laatste dagen was ik wat negatief over esperite maar dat was impulsief reageren en niet goed. Laten we positief blijven en samen zijn we sterk en kunnen we de koers deels beinvloeden! De Q1 2016 wijst op een krachtig herstel!!! Ik ga in ieder geval van start met bijkopen (ondanks de duizenden aandelen die ik al heb van esperite) Bijkomend voordeel is dat je voor jezelf middelt in de gemiddelde koers. POSITIEF BLIJVEN
    Je initiatief heeft vruchten afgeworpen.
3.912 Posts
Pagina: «« 1 ... 68 69 70 71 72 ... 196 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.